Why have drugs to treat the liver disease MASH reached a tipping point? How did Hims & Hers convince Childish Gambino to ...

Akero's success in reversing cirrhosis follows that of Madrigal, making analysts and investors bullish on drugs to treat ...

Inc. (NASDAQ:ETNB), with a market capitalization of $1.14 billion, is a clinical-stage biopharmaceutical company focusing on the development of innovative therapies for the treatment of liver and ...

In imported Lay's chips, traces of six allergens were found at once, which the manufacturer did not inform about on the ...

One of the standout projects making waves in this space is Monsta Mash, a GameFi ecosystem that is drawing significant attention from large investors due to its incredibly low entry price of $0.00365.

Akero Therapeutics (AKRO) reported 96-week data in its trial of advanced MASH patients, and there seem really significant ...

Commonwealth University’s faculty and coaches are set to take a no-confidence vote on the University’s president on February ...

Faculty and coaches from three campuses of Commonwealth University will vote anonymously in February to give their voice in ...

Akero's SYMMETRY Phase 2b study showed 50mg EFX achieved 24% cirrhosis reversal in MASH patients, with improvements in liver ...

Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. See why I continue to rate ETNB stock a buy.

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...